Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 25Genitourinary 20Lymphoid 19Other hematologic neoplasm 16Gastrointestinal 15Breast 15Plasma cell 9Dermatologic 8CNS 8Head & Neck 7Sarcoma 6Gynecologic 6Endocrine 6NET 3Other solid neoplasm 2Myeloid 2Classical hematology 1

Conditions

Solid Tumors 1KRAS p.G12C Mutant Advanced Solid Tumors 1

Interventions

sotorasib 1pralsetinib 1ipatasertib 1inavolisib 1entrectinib 1atezolizumab 1alectinib 1Midazolam 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Other solid neoplasm × 90 days × Clear all
NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

Phase 2 Active not recruiting
920 enrolled 1 FDA
Other solid neoplasm

Solid Tumors

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Amgen

Phase 1/2 Active not recruiting
713 enrolled 1 FDA
Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡